Hepatitis C Therapy

Trial data indicates Peregrine's antiviral agent Tarvacin safe, well-tolerated in HCV patients

Published in Hepatitis Weekly, March 27th, 2006

Peregrine Pharmaceuticals, Inc., (PPHM), a biopharmaceutical company with a portfolio of clinical-stage product candidates for viral diseases and cancer, announced that it will present top-line data demonstrating its first-in-class antiviral compound Tarvacin Anti-Viral appeared safe and well-tolerated in a phase l study in chronic hepatitis C virus (HCV)-infected patients.

Tarvacin Anti-Viral is the first in a new class of antiphosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-03-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry